GT
URGN icon

Glenmede Trust’s UroGen Pharma URGN Stock Holding History

Glenmede Trust’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$633K Buy
17,206
+6,689
+64% +$181K ﹤0.01% 908
2026
Q1 		$189K Buy
+10,517
New +$211K ﹤0.01% 1322

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Glenmede Trust's URGN Position: Q2 2026 in Review

Glenmede Trust increased its UroGen Pharma (URGN) stake by 64% in Q2 2026, buying an estimated $181K and bringing the position to 17,206 shares worth $633K. The position accounts for ﹤0.01% of the portfolio, ranked #908.

Glenmede Trust first reported a position in URGN in Q1 2026 and has held it in 2 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Glenmede Trust held 17,206 shares of UroGen Pharma worth $633K as of Q2 2026.
  • Glenmede Trust bought 6,689 UroGen Pharma shares in Q2 2026, an estimated $181K.
  • UroGen Pharma made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #908 holding.
  • Glenmede Trust first reported a position in UroGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.